Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that GlaxoSmithKline (GSK) has initiated two separate Phase 2b trials of GSK 2251052, or GSK '052 (formerly referred to as AN3365), in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). GSK '052 is...
Anacor Pharmaceuticals today announced the establishment of a research agreement with Eli Lilly and Company to create and develop new therapeutics for animal health. The collaboration takes advantage of Anacor's boron chemistry platform and drug research capabilities with the goal of advancing...